MorphoSys AG (0NDV.IL)

66,80 0,00 (0,00%) Alla chiusura: 05:13PM BST

MorphoSys AG

Semmelweisstrasse 7
Planegg 82152
Germany
49 89 89927 0
https://www.morphosys.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 544

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Jean-Paul Kress M.D.	Chairman of Management Board, MD & CEO	2,03M	N/D	1965
Dr. Lucinda Crabtree Ph.D.	CFO & Member of Management Board	N/D	N/D	1979
Ms. Charlotte Lohmann	Chief Legal Officer & Member of Management Board	N/D	N/D	1970
Mr. Klaus De Wall	Head of Accounting & Tax	N/D	N/D	N/D
Dr. Margit Urban	Head of Discovery Alliances & Technologies	N/D	N/D	N/D
Dr. Anja Pomrehn	Sr. VP & Head of Investor Relations	N/D	N/D	N/D
Mr. Thomas Biegi	VP & Head of Corp. Communications	N/D	N/D	N/D
Ms. Maria Castresana	Sr. VP & Global Head of HR	N/D	N/D	N/D
Dr. Barbara Krebs-Pohl Ph.D.	Chief Bus. Officer	N/D	N/D	N/D
Dr. Günter Wellnhofer	Head of Technical Operations	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule to treat myelofibrosis; Felzartamab, an antibody directed against CD38 for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule to promote anti-tumor activity by inhibiting EZH2 and EZH1. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases; and Otilimab, an antibody for rheumatoid arthritis. The company has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

Governance aziendale

L'ISS Governance QualityScore di MorphoSys AG al 1 ottobre 2023 è 1. I criteri di valutazione fondamentali sono revisione: 2; Consiglio di Amministrazione: 1; diritti degli azionisti: 1; retribuzione: 6.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.